


PHARMACEUTICAL 2021

GERON CORP Rank 141 of 409





PHARMACEUTICAL 2021

GERON CORP Rank 141 of 409



The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of GERON CORP is the variable Revenues, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is -45%, being 309% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	199,857
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,940
Liabilities, Non-Current	28,841
Other Assets	70,213
Other Compr. Net Income	-54
Other Expenses	760
Other Liabilities	0
Other Net Income	2,056
Property and Equipment	658
Research and Development	51,488
Revenues	253
Selling, General and Administrative Expense	25,678

Output Variable	Value in 1000 USD
Assets	270,728
Liabilities	59,781
Expenses	77,926
Stockholders Equity	210,947
Net Income	-75,617
Comprehensive Net Income	-75,644
Economic Capital Ratio	-45%

